Vor Biopharma (VOR) Stock Forecast & Price Target

Vor Biopharma is a clinical-stage biopharmaceutical company with a promising candidate, telitacicept, that has shown consistently positive results in late-stage China studies across multiple key B-cell-mediated autoimmune indications. The recent NEJM publication of an interim analysis for telitacicept in IgA nephropathy further validates its franchise potential, with a significant reduction in proteinuria, a stable eGFR, and a favorable safety profile. With a strong cash position of $491.5MM and ongoing trials in other indications, including myasthenia gravis and Sjögren’s disease, Vor Biopharma has the potential to be a leader in the biopharmaceutical world for immunology and inflammation treatments.

Vor Biopharma is facing significant challenges due to its lack of current revenue and high net losses reported in its 1Q26 financial results. With projected revenues of $0 for 2026, the company's cash and marketable securities may only last until early 2029, making it crucial for the company to successfully bring its novel therapy for autoimmune diseases to market in a timely manner to generate revenue and sustain operations. The company's valuation also relies heavily on its ability to bring its clinical-stage candidates to market, with a sum-of-parts valuation based on 2033-34E sales and risk-adjusted rates.